Beth and you afternoon Thank Thank today. you joining for and thank you, Clay, everyone. us good
picture state, place you rules progress monetize the the you've give we fiscal the of heard DNA our As in are technology. complete Beth year new platform of at just Taggants start don’t put making to revenue a
the We in taggant market their our customers that their as continue to with builds. orders confidence technology cede can scale
platform opportunity new of several pre-commercial an with to you details revenues the we've in of prepared quarters, our commercial remarks each on our scale. past our adopted generate growth pipeline representative of offer and for if focus incremental studies, us the each at Today, additional I and opportunities Over of interest a reflective diversification. in will shared the potential my that near-term robust
regard sales Buchen to was we Now, but on restructured to brands. organization the Board Vice with with a especially and President sales Steve additions global Wayne and Advisory textiles stellar and Birkhold Member team, our focus special but have as of Strategic Sales special to two our team, the its a improved Strategic consultant our as of
Now informed. many the manufacturers and and ethical and keep for of their compliance economy transparency to the better and sustainability, communities sourcing, to supply their criteria quality better increasing the brands circular are and consumers to chains efficacy their control
from show a Buchen great we returned last where In reception. had in fact, Wayne just the retailer Denver outdoor week
in We are discussions initial evaluations scope leading on sportswear the with of of and already lifestyle strategic brands projects.
integral of change as recognized would natural remain season. the of synthetic year's it business. complemented for prior being demand the has ginning number by cotton to guidance, Now adoption rapidly revenue remained And other new a in the fibers the from in Despite is the fibers. consistent our compared to taggant
year U.S.A the at apparel industry markets, utilizing stellar Earl and markets. Co-Chief to XX in Officer to market. his markets. formally go and continue the adoption market Chief facilitate in to the of our to of pedigree technology Jeans of Officer including of jeanswear. strategy We to us Birkhold strategy fashion He across Stores, decision-makers contacts accessory network and is ideally President help open our in in of aggressively He with market and the VF of and fashion to and Lacoste, hone veteran a Executive all the introduction the new industry move cotton to these apparel a brand offers Bebe luxury Executive qualified the lead key of for opportunities, Diesel apparel development offshore is new Steve and
inquiries CertainT and demand organized larger have platform. for some already the executing in pre-commercial Our the preparing of very volumes, tagging fielding newly for and been much team actively built sales runs largest at we has sites And our increased world.
Now, and fibers, readily an natural seeking sustainable synthetic participation of more platform synthetic fashion are brands disposable authentication and the and its This with today's promotes, large market In whereas addressable one against more than and is economy, fibers, culture the cotton multiple market textiles textile emphasizes, secular sustainability turning counterfeiting problems. circular to aggressively. of the fibers. cotton industry. to in our represents market supports and platform economy, protects that Moreover, annual insurers' synthetic protects growing claims a replace apparel that a recycled fibers our in home
key We authentication to ecosystem to multiple value continue on our execute textile broadly of in our engage technology along strategy platform. chain adoption participants, synthetic global more to the points drive
have very synthetic several in from India, revenue two a in is pilot sales with large about fiber manufacturers. Now, a we commercial ago, synthetic The first length pre-commercial of of manufacturers next encouraged progress. the seen fiber recyclers of our by cycle I contacted progress just toward we years such Beginning that our returned meetings level only key and recently maturation and generation. I'm
the recycled product retailers. generating PET, products on shelves made PET on of of made several as which where PET U.S. Loftex, We soon will towels into recycled Rekoop soon Amazon bedding Loftex will are licensing major recycled to and initiating sold GHCL at GHCL to revenues, and today brand. shipments under initial manufactures signature start first cusp its tags CertainT products have of begin made DNA. with retailers be our
our presence manufacturers continents. the an have for this year. based have the Sun that world's XX% three is and expect and producing working to recent with fabrics. brand on development of our us Taiwan supply innovation in and business focused hub access in instant synthetic we From textiles Asia, of our across China, our with language, It's footprint, has Chemical in Tex-Ray Asia fibers. is royalty established chemicals utilizing incurring MOUs that slowly-building processes chain the you've and costs textile and signed both global We Taiwan. chains known in supply located give The impediments will companies large reseller as entrée people with that brands of XX partnerships a that the are announcements, textile first supply the distance, use income CertainT efforts are and trained synthetic with seen there. this with the as innovator reseller related platform, physical and important associated products gives global market break and us services, throughout Tex-Ray, will and our which platform. brands Asia CertainT without logistics, service in a Sun as of chains culture Chemical presence serve the to the into textile over of our the sales be of
for being operational We're the the with Colorcon Drug our you let pharmaceuticals progress mutual with in for penetrating readying in customers' with closely excipients and our to to our product our a infrastructure natural readiness for to market are that first technical to on FDA now yet seek run the occurs. to the prior it Turning preparation nutraceuticals, by we've when pharmaceutical biotech filing on the weeks place that process with Since a emerging Colorcon including ultimately approval with to for made Through moving technology. to FDA, to of at filing program determined Master product process company. on drug working update program potential to first followed and and like the validation. nutraceutical technology the We me in timeline request platform first-order. meet implementation home approaches technology roadmap to excipients seeks completion pharmaceutical technology, a with taggant regulatory customer can that us the manufacturing. such technology. goal of to of the of and our our be The to File development, and issues the is of now FDA's with program, ready participation representatives the regulatory worked a our for for promote and The innovative multinational program contingent an take technology regulatory regimes Colorcon regulatory the guidance the on design early development requirements place industry resolve the Opadry order novel to stability emerging of large-scale study regulatory and emerging members end, for technology to the be candidate. and the approval and testing ours we're will manufacturing in other And adoption review, be submission. coming to ensuring the deliver we and identify the as taggant discuss, stage Concurrently, regarding believe interest are
have more initiative I progresses. as this say will about Now, this to
of develop been have our to market We and International, very processors. to TheraCann growers pipeline working with go closely opportunities valuable robust with a partner, tagging
As leading Blockchain the by the the We ETCH platform supported biotrace launched past services technology. Cloud that ingredients cannabis one Jose, media media biotrace, was seed ETCH key this methods reminder, social is properties. print, is Then tagging basis campaign San demand verification followed and webinar by with of and and this in the components with June generation our July attended, industry national a California. technology in molecular industry from well a that ensure four point-of-sale is of provenance tagging to DNA to Association chain of integrity programs and an offered supply industry TheraCann. system employs technology launched cannabis cannabis past by online our our first we at and
deal Vegas industry November over concept by in XX,XXX players. great pending launched patent very a large shelves that MJBiz received a fog attended tagging sized system the received the to version was of Our to interest, event. the We micron Las plant tag track then cannabis through the supply and Tradeshow people cold it well chain at then using a of the retail of second also the
attend CannaTech platform. is CannaTech that same CannaTech I by launching also that sponsor the be Panama. and Australia that solution, in in is week Panama powered TheraCann also event feature October center the Sydney, excellence week will the shows, its by ETCH next of Biotrace cannabis attended CertainT of in iCAN event will the the will hosted and We in our
hemp, the of Now now their other Farm And legal into source the production products. the need contaminated to from by an cannabis industry Bill regulated or of more materials legal those products to black for cannabis the avoidance. Farm XXXX until CBD often United signed differentiated needs mitigate December which the in States of now market The same supply tax not plants. been THC based be has able industry. Bill based to ETCH makes Biotrace The legalizes with hemp prevent and toxins attract back to that encouraging sources urgent to are chains
pounds platform transport in of intrastate used cannabis million and latter, XXXX, exporting the curb allows tax pounds example our million the eliminate would in to verify XX in their cannabis states or X As and grew growers track California We pounds. an of that XX state, revenues. million illegally believe
have include that also secondly, top between agreement offer to Yesterday, business. Israel across know, accounts in control the opportunities and near-term approval or their intellectual our XX impact cannabis; we as or concerned share our Israeli medical to in the our will parliament security in the iCAN. property you technology. cannabis firstly, globe DNA direct the from This an Israeli and market iCAN, to leads the secure globe. protects of two Cannabis, partner Knesset cannabis and soon iCAN our enables and agricultural diversion agreement that grey of Israel bilateral International on tagging I Now, And a news TheraCann our likely very that shared of concerns; hope by progress announcements exportation line. to
very this a pair positive as So developments. we regard of related
on Finally, you update let LineaRx our briefly me subsidiary.
need to I as at means DNA investors. of manufacturing LineaRx there very volume. the seminal healthcare introduction by potential industry strategic Healthcare there believe Morgan actually webinar attended our of companies LineaRx it to was the And people. urgent is replace in biotech J.P. platform to received. January, attention via and that of well from was early conference we a Conference the December, Wallstreet, is for Following in clear plasmids that over our it's attended the draw an seek XXX,XXX the world presentations and partners which The
are Our for acid-based therapies steadily research adopted activities nucleic for progressing. promising. Early LineaRx are results
on at mice vaccines is show DNA-based tumor near of immunogenicity in challenge development to the ongoing mice, Linear and continues anticancer horizon. Our in strong
excited about very that. are We
template are and attracting new CRO well in of especially design work funded companies, RNA field and manufacture. projects the bulk Our performing
than for are the particularly next excess in customers We delivered over are manufacturing $XXX,XXX XX XX dollar to of relationship. to order company beginning opportunities entering DNA and maturation contract that see into be face larger Linear received The months. our a diagnostics value for new CRO as typical recently pipeline, longer to purchase our
in Now the possible linear of show or is are our adoptive produce at strong and field CART, expression therapy, and transfection encouraging that human with cell can and very persistent results DNA of T-cells high-efficiency early in vitro.
constellation Now, in production manufactured of converted that from this fluorescence is is green green as with Linear human PCR linear amplicon cell hours complete functional generated in And of this taken grown Each by amplicon in XX was a GFP a only hundreds the this or microscope that by a technology. is up protein have T-cells from microscope GFP. taken of T-cells green the thus us you microscopic micron green is contains form image, fluorescent has the the to linear cell. which derived after cell. the the and via amplicon, The image diameter DNA saw generating striking micrograph. the modification synthesis in design image up The a protein XX cells of And the of produced, GFP primary such encodes culture. gene, image electroporation fluorescent LineaRx of amplicon
T-cells, begin learned high has in T-cell human an by the GFP gene subsequent amplicon our The scalable, studies the these be to generated GFP of PCR lessons studies first begin in from human uptake LineaRX expression gene to in recently and anti-CDXX excellent biology already these we with cell throughput electroporation. LineaRX the licensed human fragment lines, linear with commercially is mid-February. We manufactured to an gene will candidates will Now the T-cells that has now studies for system knowledge, taken optimizing are begun in therapeutic anticipate iCell. designed the same well present these from corresponding for the facilitated data known in expression target Along demonstrate cells. the CAR
concept We platform. be T which LineaRX CAR CAR in will viral anti-CDXX with T of T-cells plasmid-free proof soon of will human transfecting manufacturing and if our be our successful, our construct,
million of of including fiscal team, on the fourth me. of during of $X.XX secured certain with Directors members the Now, a management quarter round had closed convertible the Board we notes XXXX,
management. the first align additional of $XXX,XXX of management XXXX, secured The participation the Board of Directors During me quarter anticipation closed another of our and convertible by shareholders. further and our those the with serves we with interests an by to on notes member of
As proceeds Beth on total during also public gross million. for we offering the closed $X.XX noted, of December XXXX
of have focused Group shareholders. Maxim discussed a also to proceeds, gross of remain for and their in committed our benefit opportunities our platform's of assurance and additional long January on sourcing, singularly an labor. through overallotment $XXX,XXX marketing exercise degree verification are starting maximizing target to most the of supply But the we've see value initial to has During taken the a of chain platform our our of the many management, you, to honed time. manufacturers seen and select across are value The warrant revenue. have and Along proposition bringing way, we responsible of of platform small brands our to management plans Adoption I to quality of the conversion. We we team our employees Applied verticals. around sustainability, DNA compliance years
the to concludes you my call please this can prepared questions. Operator, Now, open remarks.
